Aetna
Aetna Aetna
Specialty Pharmacy Clinical Policy Bulletins
Aetna Non-Medicare Prescription Drug Plan
Subject: Specialty Quantity Limit Epidiolex 2611-H P2024

Drug
EPIDIOLEX  (cannabidiol)


Policy:

I.  PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If the member’s plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization.


II.  COVERED QUANTITIES

          Medication

          Standard Limit

          Exception Limit*

          FDA-recommended dosing

 

  Epidiolex (cannabidiol) 100 mg/mL oral solution

 

  800 mL per 30 days

 

  1500 mL per 30 days

  Seizures Associated with Lennox-Gastaut Syndrome or
  Dravet Syndrome
  •   Initial dose: 2.5 mg/kg twice daily (5 mg/kg/day).
      After one week, increase to a maintenance dose of 5
      mg/kg twice daily (10 mg/kg/day).
  •   May increase in weekly increments of 2.5 mg/kg
      twice daily (5 mg/kg/day) to a maximum
      maintenance dose of 10 mg/kg twice daily (20
      mg/kg/day). If more rapid titration is warranted, the
      dosage may be increased no more frequently than
      every other day.

  Seizures Associated with Tuberous Sclerosis Complex
  •   Initial dose: 2.5 mg/kg twice daily (5 mg/kg/day).
      Increase to a maintenance dose of 12.5 mg/kg twice
      daily (25 mg/kg/day) in weekly increments of 2.5
      mg/kg twice daily (5 mg/kg/day). If more rapid
      titration is warranted, the dosage may be increased
      no more frequently than every other day.

  Dose adjustment
  •   With a strong inducer of CYP3A4 or CYP2C19:
      Dose increase of Epidiolex may be considered
      based on clinical response and tolerability.

*Coverage up to the exception limit may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.

 


Place of Service:

Outpatient

The above policy is based on the following references:
  1. Epidiolex [package insert]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; March 2024.
Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

October 30, 2024
Aetna
Skip Past Footer Links
Company Information   |   Site Map Aetna.com Home   |   Help   |   Contact Us   |   Search
Web Privacy Statement   |   Legal Statement   |   Privacy Notices   |   Member Disclosure

Back to top